WO2021006845A3 - Smart temperature-sensitive hydrogels with antifungal property that perform controlled drug release - Google Patents

Smart temperature-sensitive hydrogels with antifungal property that perform controlled drug release Download PDF

Info

Publication number
WO2021006845A3
WO2021006845A3 PCT/TR2020/050592 TR2020050592W WO2021006845A3 WO 2021006845 A3 WO2021006845 A3 WO 2021006845A3 TR 2020050592 W TR2020050592 W TR 2020050592W WO 2021006845 A3 WO2021006845 A3 WO 2021006845A3
Authority
WO
WIPO (PCT)
Prior art keywords
antifungal property
drug release
controlled drug
antifungal
perform controlled
Prior art date
Application number
PCT/TR2020/050592
Other languages
French (fr)
Other versions
WO2021006845A2 (en
Inventor
Bahar KANCI BOZOGLAN
Sibel TUNC
Osman Duman
Original Assignee
Akdeniz Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akdeniz Universitesi filed Critical Akdeniz Universitesi
Priority to EP20836170.9A priority Critical patent/EP3996748A4/en
Publication of WO2021006845A2 publication Critical patent/WO2021006845A2/en
Publication of WO2021006845A3 publication Critical patent/WO2021006845A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Abstract

The present invention relates to temperature-sensitive smart hydrogels that feature antifungal property and perform controlled drug release. Smart hydrogels were developed to be used in the treatment of nail fungus. The inventive hydrogel formula comprises at least one natural polymer (polysaccharide and/or protein) additive, at least one inorganic or organic additive, and an active pharmaceutical ingredient with antifungal property. The antifungal drug in hydrogel formulation is released in a controlled manner, and this not only shortens the treatment period but also reduces the amount of the drug administered since the necessity for regularly administering drugs to the fungal infection area is eliminated.
PCT/TR2020/050592 2019-07-09 2020-07-07 Smart temperature-sensitive hydrogels with antifungal property that perform controlled drug release WO2021006845A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20836170.9A EP3996748A4 (en) 2019-07-09 2020-07-07 Smart temperature-sensitive hydrogels with antifungal property that perform controlled drug release

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2019/10214A TR201910214A2 (en) 2019-07-09 2019-07-09 INTELLIGENT HYDROGELS WITH ANTIFUNGAL FEATURES THAT DELIVER CONTROLLED DRUGS SENSITIVE TO TEMPERATURE
TR2019/10214 2019-07-09

Publications (2)

Publication Number Publication Date
WO2021006845A2 WO2021006845A2 (en) 2021-01-14
WO2021006845A3 true WO2021006845A3 (en) 2021-03-11

Family

ID=74114203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2020/050592 WO2021006845A2 (en) 2019-07-09 2020-07-07 Smart temperature-sensitive hydrogels with antifungal property that perform controlled drug release

Country Status (3)

Country Link
EP (1) EP3996748A4 (en)
TR (1) TR201910214A2 (en)
WO (1) WO2021006845A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160613B (en) * 2022-08-17 2023-07-18 江苏省农业科学院 Preparation process of fresh-keeping hydrogel film
CN117700777B (en) * 2024-02-06 2024-04-09 上海瑛泰璞润医疗器械有限公司 Ultrasonic temperature measurement gel and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101260191A (en) * 2008-04-01 2008-09-10 武汉大学 Temperature sensitive type chitosan/glutin hydrogel and its preparation method and use
WO2010109418A1 (en) * 2009-03-25 2010-09-30 Sulur Subramaniam Vanangamudi A medicinal antifungal cream and a process to make it
WO2013045729A1 (en) * 2011-09-29 2013-04-04 Universidade De Santiago De Compostela Cyclodextrin nanogels
WO2014005471A1 (en) * 2012-07-06 2014-01-09 中国科学院大连化学物理研究所 Thermosensitive injectable chitosan hydrogel product and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024489D0 (en) 2000-10-06 2000-11-22 Reckitt Benckiser Uk Ltd Improvements in or relating to organic compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101260191A (en) * 2008-04-01 2008-09-10 武汉大学 Temperature sensitive type chitosan/glutin hydrogel and its preparation method and use
WO2010109418A1 (en) * 2009-03-25 2010-09-30 Sulur Subramaniam Vanangamudi A medicinal antifungal cream and a process to make it
WO2013045729A1 (en) * 2011-09-29 2013-04-04 Universidade De Santiago De Compostela Cyclodextrin nanogels
WO2014005471A1 (en) * 2012-07-06 2014-01-09 中国科学院大连化学物理研究所 Thermosensitive injectable chitosan hydrogel product and use thereof

Also Published As

Publication number Publication date
WO2021006845A2 (en) 2021-01-14
EP3996748A2 (en) 2022-05-18
TR201910214A2 (en) 2021-01-21
EP3996748A4 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
MX2020007625A (en) Mtor inhibitor, pharmaceutical composition and use thereof.
MX2021004546A (en) Implantable drug delivery compositions and methods of use thereof.
WO2021006845A3 (en) Smart temperature-sensitive hydrogels with antifungal property that perform controlled drug release
US9044488B2 (en) Medicinal cream made using silver sulphadiazine and chitosan and a process to make it
CA3030422C (en) Stabilizing excipients for therapeutic protein formulations
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
DE602006014990D1 (en) INTRANASAL ADMINISTRATION OF FAST-ACTING INSULIN
ATE544447T1 (en) MEDICINAL COATING WITH A HIGH ACTIVE INGREDIENTS CONTENT AND METHODS FOR THE PRODUCTION THEREOF
WO2005011813A3 (en) Treatment of ocular disease
ATE509616T1 (en) TOPICAL PHARMACEUTICAL AND/OR COSMETIC DOSAGE SYSTEMS
ATE428401T1 (en) SUSPENSION FORMULATIONS CONTAINING AN ACTIVE INGREDIENT, A POLOXAMER OR MEROXAPOL SURFACTANT AND A GLYCOL AND THEIR USE IN THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF EYE DISEASES
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
JP2015007136A5 (en)
WO2009058585A3 (en) Non-aqueous water-miscible materials as vehicles for drug delivery
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2023129738A3 (en) Modified polysaccharide polymers and related compositions and methods thereof
CA2519789A1 (en) Aplidine for multiple myeloma treatment
WO2006012146A3 (en) Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
WO2019118779A3 (en) Peptides and other agents for treating pain and increasing pain sensitivity
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
EP3210619A2 (en) Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
CN108367026A (en) Antimicrobial preparation
AR054710A1 (en) FORMULATION OF MUTED PROTEINS OF STAPHYLOCOCCAL ENTEROTOXIN C1 (SEC1) AND METHOD FOR FORMULATION
BR112021016795A8 (en) ADMINISTRATION OF JUICE ACTIVATING ENZYME INHIBITOR AND CHECKPOINT INHIBITORS
MX2022011961A (en) Composition having improved voluntary acceptance.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20836170

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020836170

Country of ref document: EP

Effective date: 20220209